Rynatuss Tablets
Generic name: carbetapentane tannate, chlorpheniramine tannate, ephedrine tannate, and phenylephrine tannate
Dosage form: tablet
Drug class:Upper respiratory combinations
Medically reviewed by Drugs.com. Last updated on May 23, 2022.
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
On This Page
Description
RYNATUSS® Tablets are an antitussive/antihistamine/nasal decongestant/bronchodilator combination.
Each tablet contains:
Carbetapentane Tannate 60 mg
Chlorpheniramine Tannate 5 mg
Ephedrine Tannate 10 mg
Phenylephrine Tannate 10 mg
Other ingredients: corn starch, dibasic calcium phosphate, FD&C Blue No. 1, FD&C Red No. 40, magnesium stearate, methylcellulose, polygalacturonic acid, povidone, talc.
Clinical Pharmacology
RYNATUSS® Tablets combine the antitussive action of carbetapentane, the sympathomimetic decongestant effect of phenylephrine, the antihistaminic action of chlorpheniramine, and the bronchodilator action of ephedrine.
Indications and Usage
RYNATUSS® Tablets are indicated for the symptomatic relief of cough associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis. Appropriate therapy should be provided for the primary disease.
Contraindications
RYNATUSS® Tablets are contraindicated for newborns, nursing mothers, and patients who are sensitive to any of the ingredients or related compounds.
Warnings
Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, narrow angle glaucoma, or prostat
